systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-296Research ArticleМЕТАБОЛИЧЕСКИЕ НАРУШЕНИЯMETABOLIC DISTURBANCESЭффективность ирбесартана при артериальной гипертонии и метаболическом синдромеEfficacy of irbesartan in arterial hypertension and metabolic syndromeОстроумоваО. Д.OstroumovaO. D.ostroumova.olga@mail.ruЗыковаА. А.ZykovaA. A.noemail@neicon.ruПолосоваТ. А.PolosovaT. A.noemail@neicon.ruБондарецО. В.BondaretsO. V.noemail@neicon.ruГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава РФ;ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФRussian FederationГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава РФRussian Federation2013231220221025356Copyright © Остроумова О.Д., Зыкова А.А., Полосова Т.А., Бондарец О.В., 20222022Остроумова О.Д., Зыкова А.А., Полосова Т.А., Бондарец О.В.Ostroumova O.D., Zykova A.A., Polosova T.A., Bondarets O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/296

В статье приведены данные Российских рекомендаций по диагностике и подходам к лечению метаболического синдрома. Рассмотрены вопросы выбора антигипертензивных препаратов для лечения артериальной гипертонии у лиц с метаболическим синдромом. Показаны преимущества назначения блокаторов рецепторов к ангиотензину II. Анализируются результаты ряда исследований по эффективности и безопасности применения ирбесартана для лечения артериальной гипертонии при метаболическом синдроме.

The paper gives the data of Russian guidelines for the diagnosis and approaches to treating metabolic syndrome. It considers the choice of antihypertensive drugs in the treatment of hypertensive patients with metabolic syndrome. The benefits of angiotensin II receptor blockers are shown. The results of a number of trials evaluating the efficacy and safety of irbesartan used to manage arterial hypertension in metabolic syndrome are analyzed.

артериальная гипертонияметаболический синдромантигипертензивная терапияблокаторы рецепторов к ангиотензину IIирбесартанarterial hypertensionmetabolic syndromeantihypertensive therapyangiotensin II receptor blockersirbesartanReferencesРекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. Второй пересмотр. Кардиоваскулярная терапия и профилактика. 2009; 6 (Прил. 2): 1–29.Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. Второй пересмотр. Кардиоваскулярная терапия и профилактика. 2009; 6 (Прил. 2): 1–29.Lakka H.M, Laaksonen D.E, Lakka T.A et al. The metabolic syndrome and total and cardiovascular disease mortality in middle - aged men. JAMA 2002; 288: 2709–16.Lakka H.M, Laaksonen D.E, Lakka T.A et al. The metabolic syndrome and total and cardiovascular disease mortality in middle - aged men. JAMA 2002; 288: 2709–16.Howard G, O'Leary D.H, Zaccaro D et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996; 93 (10): 1809–17.Howard G, O'Leary D.H, Zaccaro D et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996; 93 (10): 1809–17.Mule G, Nardi E, Cottone S et al. Infl uence of metabolic syndrome on hypertension - related target organ damage. J Intern Med 2005; 257: 503–13.Mule G, Nardi E, Cottone S et al. Infl uence of metabolic syndrome on hypertension - related target organ damage. J Intern Med 2005; 257: 503–13.Schilacci G, Pirro M, Vaudo G et al. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 2005; 45: 1978–82.Schilacci G, Pirro M, Vaudo G et al. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 2005; 45: 1978–82.Cuspidi C, Meani S, Fusi V et al. Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: the Evaluation of Target Organ Damage in Hypertension study. J Hypertens 2005; 23: 875–82.Cuspidi C, Meani S, Fusi V et al. Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: the Evaluation of Target Organ Damage in Hypertension study. J Hypertens 2005; 23: 875–82.Kavamoto R, Tomita H, Oka Y et al. Metabolic syndrome amplifi es the LDL - cholesterol associated increases in carotid atherosclerosis. Intern Med 2005; 44: 1232–8.Kavamoto R, Tomita H, Oka Y et al. Metabolic syndrome amplifi es the LDL - cholesterol associated increases in carotid atherosclerosis. Intern Med 2005; 44: 1232–8.Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5–26.Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5–26.Клиническая фармакология. Под ред. В.Г.Кукеса. 4 - е изд. М.: ГЭОТАР - Медиа, 2008; с. 392–5.Клиническая фармакология. Под ред. В.Г.Кукеса. 4 - е изд. М.: ГЭОТАР - Медиа, 2008; с. 392–5.Dahlof B, Devereux R.B, Kjeldsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.Dahlof B, Devereux R.B, Kjeldsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.Julius S, Kjeldsen S.E, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.Julius S, Kjeldsen S.E, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.Pfeffer M.A, Swedberg K, Granger C.B et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362 (9386): 759–66.Pfeffer M.A, Swedberg K, Granger C.B et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362 (9386): 759–66.Neutel J.M, Saunders E, Bakris G.L et al. The efficacy and safety of lowand high - dose fixed combinations of irbe irbesartan/HCTZ in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005; 7: 578–86.Neutel J.M, Saunders E, Bakris G.L et al. The efficacy and safety of lowand high - dose fixed combinations of irbe irbesartan/HCTZ in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005; 7: 578–86.Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. М.: Медиа Медика, 2007; с. 56–73.Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. М.: Медиа Медика, 2007; с. 56–73.Sowers J.R, Neutel J.M, Saunders E et al. Behalf of the INCLUSIVE Investigators. Antihypertensive Efficacy of Irbesartan/HCTZ in Men and Women With the Metabolic Syndrome and Type 2 Diabetes. J Clin Hypertens 2006; 8: 470–80.Sowers J.R, Neutel J.M, Saunders E et al. Behalf of the INCLUSIVE Investigators. Antihypertensive Efficacy of Irbesartan/HCTZ in Men and Women With the Metabolic Syndrome and Type 2 Diabetes. J Clin Hypertens 2006; 8: 470–80.Parhofer K.G, Münzel F, Krekler M. Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO - IT prospective observational study. Cardiovasc Diabetol 2007; 6: 36.Parhofer K.G, Münzel F, Krekler M. Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO - IT prospective observational study. Cardiovasc Diabetol 2007; 6: 36.Kintscher U, Bramlage P, Paar W.D et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007; 6: 12.Kintscher U, Bramlage P, Paar W.D et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007; 6: 12.

The authors declare that there are no conflicts of interest present.